Scolaris Content Display Scolaris Content Display

Adjuvant anti‐VEGF therapy for overall survival and relapse‐free survival in patients with resected non‐metastatic colorectal cancer

This is not the most recent version

Appendices

Appendix 1. CENTRAL search strategy

Cochrane Central Register of Controlled Trials (latest Issue)

#1 MeSH descriptor: [Colorectal Neoplasms] explode all trees
#2 MeSH descriptor: [Intestine, Large] explode all trees
#3 (colorect* or colon* or rectal or rectum or anal* or anus* or intestin* or bowel* or abdom*) near/3 (carcinom* or neoplas* or adenocarcinom* or cancer* or tumor* or tumour* or sarcom* or polyp*):ti,ab,kw
#4 (#1 or #2 or #3)
#5 MeSH descriptor: [Vascular Endothelial Growth Factors] explode all trees
#6 MeSH descriptor: [Receptors, Vascular Endothelial Growth Factor] explode all trees
#7 MeSH descriptor: [Angiogenesis Inhibitors] explode all trees
#8 (vascular endothelial growth factor or VEGF or VEGFR or FGFR or fibroblast growth factor or Bevacizumab or Aflibercept or Regorafenib):ti,ab,kw
#9 (#5 or #6 or #7 or #8)
#10 (#4 and #9)

Appendix 2. MEDLINE search strategy

Ovid MEDLINE (1950 to date)

1. exp Colorectal Neoplasms/
2. exp Intestine, Large/
3. ((colorect* or colon* or rectal or rectum or anal* or anus* or intestin* or bowel* or abdom*) adj3 (carcinom* or neoplas* or adenocarcinom* or cancer* or tumor* or tumour* or sarcom* or polyp*)).mp.
4. 1 or 2 or 3
5. exp Vascular Endothelial Growth Factors/
6. exp Receptors, Vascular Endothelial Growth Factor/
7. exp Angiogenesis Inhibitors/
8. (vascular endothelial growth factor or VEGF or VEGFR or FGFR or fibroblast growth factor or Bevacizumab or Aflibercept or Regorafenib).mp.
9. 5 or 6 or 7 or 8
10. 4 and 9
11. randomized controlled trial.pt.
12. controlled clinical trial.pt.
13. random*.ab.
14. placebo.ab.
15. drug therapy.fs.
16. trial.ab.
17. groups.ab.
18. 11 or 12 or 13 or 14 or 15 or 16 or 17
19. exp animal/ not humans.sh.
20. 18 not 19
21. 10 and 20

Appendix 3. Embase search strategy

Ovid Embase (1974 to date)

1. exp colorectal cancer/
2. exp large intestine/
3. ((colorect* or colon* or rectal or rectum or anal* or anus* or intestin* or bowel* or abdom*) adj3 (carcinom* or neoplas* or adenocarcinom* or cancer* or tumor* or tumour* or sarcom* or polyp*)).mp.
4. 1 or 2 or 3
5. exp vasculotropin/
6. exp vasculotropin receptor/
7. exp angiogenesis inhibitor/
8. (vascular endothelial growth factor or VEGF or VEGFR or FGFR or fibroblast growth factor or Bevacizumab or Aflibercept or Regorafenib).mp.
9. 5 or 6 or 7 or 8
10. 4 and 9
11. CROSSOVER PROCEDURE.sh.
12. DOUBLE‐BLIND PROCEDURE.sh.
13. SINGLE‐BLIND PROCEDURE.sh.
14. (crossover* or cross over*).ti,ab.
15. placebo*.ti,ab.
16. (doubl* adj blind*).ti,ab.
17. allocat*.ti,ab.
18. trial.ti.
19. RANDOMIZED CONTROLLED TRIAL.sh.
20. random*.ti,ab.
21. 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20
22. (exp animal/ or exp invertebrate/ or animal.hw. or nonhuman/) not (exp human/ or human cell/ or (human or humans or man or men or wom?n).ti.)
23. 21 not 22
24. 10 and 23
25. 10 and 23

Appendix 4. Criteria for judging risk of bias in the Cochrane 'Risk of bias' assessment t ool

Random sequence generation: selection bias (biased allocation to interventions) due to inadequate generation of a randomized sequence

Criteria for a judgement of ‘low risk’ of bias.

The investigators describe a random component in the sequence generation process such as:

  • referring to a random number table;

  • using a computer random number generator;

  • coin tossing;

  • shuffling cards or envelopes;

  • throwing dice;

  • drawing of lots;

  • minimization¹.

¹Minimization may be implemented without a random element, and this is considered to be equivalent to being random.

Criteria for the judgement of ‘high risk’ of bias.

The investigators describe a non‐random component in the sequence generation process. Usually, the description would involve some systematic, non‐random approach, for example:

  • sequence generated by odd or even date of birth;

  • sequence generated by some rule based on date (or day) of admission;

  • sequence generated by some rule based on hospital or clinic record number.

Other non‐random approaches happen much less frequently than the systematic approaches mentioned above and tend to be obvious. They usually involve judgement or some method of non‐random categorization of participants, for example:

  • allocation by judgement of the clinician;

  • allocation by preference of the participant;

  • allocation based on the results of a laboratory test or a series of tests;

  • allocation by availability of the intervention.

Criteria for the judgement of ‘unclear risk’ of bias.

Insufficient information about the sequence generation process to permit judgement of ‘low risk’ or ‘high risk’.

Allocation concealment: selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment.

Criteria for a judgement of ‘low risk’ of bias.

Participants and investigators enrolling participants could not foresee assignment because 1 of the following, or an equivalent method, was used to conceal allocation:

  • central allocation (including telephone, web‐based and pharmacy‐controlled randomization);

  • sequentially numbered drug containers of identical appearance;

  • sequentially numbered, opaque, sealed envelopes.

Criteria for the judgement of ‘high risk’ of bias.

Participants or investigators enrolling participants could possibly foresee assignments and thus introduce selection bias, such as allocation based on:

  • using an open random allocation schedule (e.g. a list of random numbers);

  • assignment envelopes were used without appropriate safeguards (e.g. if envelopes were unsealed or non­opaque or not sequentially numbered);

  • alternation or rotation;

  • date of birth;

  • case record number;

  • any other explicitly unconcealed procedure.

Criteria for the judgement of ‘unclear risk’ of bias.

Insufficient information to permit judgement of ‘low risk’ or ‘high risk’. This is usually the case if the method of concealment is not described or not described in sufficient detail to allow a definite judgement; for example if the use of assignment envelopes is described, but it remains unclear whether envelopes were sequentially numbered, opaque and sealed.

Blinding of participants and personnel: performance bias due to knowledge of the allocated interventions by participants and personnel during the study.

Criteria for a judgement of ‘low risk’ of bias.

Any 1 of the following:

  • no blinding or incomplete blinding, but the review authors judge that the outcome is not likely to be influenced by lack of blinding;

  • blinding of participants and key study personnel ensured, and unlikely that the blinding could have been broken.

Criteria for the judgement of ‘high risk’ of bias.

Any 1 of the following:

  • no blinding or incomplete blinding, and the outcome is likely to be influenced by lack of blinding;

  • blinding of key study participants and personnel attempted, but likely that the blinding could have been broken, and the outcome is likely to be influenced by lack of blinding.

Criteria for the judgement of ‘unclear risk’ of bias.

Any 1 of the following:

  • insufficient information to permit judgement of ‘low risk’ or ‘high risk’;

  • the study did not address this outcome.

Blinding of outcome assessment: detection bias due to knowledge of the allocated interventions by outcome assessors.

Criteria for a judgement of ‘low risk’ of bias.

Any 1 of the following:

  • no blinding of outcome assessment, but the review authors judge that the outcome measurement is not likely to be influenced by lack of blinding;

  • blinding of outcome assessment ensured, and unlikely that the blinding could have been broken.

Criteria for the judgement of ‘high risk’ of bias.

Any 1 of the following:

  • No blinding of outcome assessment, and the outcome measurement is likely to be influenced by lack of blinding;

  • Blinding of outcome assessment, but likely that the blinding could have been broken, and the outcome measurement is likely to be influenced by lack of blinding.

Criteria for the judgement of ‘unclear risk’ of bias.

Any 1 of the following:

  • Insufficient information to permit judgement of ‘low risk’ or ‘high risk’;

  • the study did not address this outcome.

Incomplete outcome data: attrition bias due to amount, nature or handling of incomplete outcome data.

Criteria for a judgement of ‘low risk’ of bias.

Any 1 of the following:

  • no missing outcome data;

  • reasons for missing outcome data unlikely to be related to true outcome (for survival data, censoring unlikely to be introducing bias);

  • missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups;

  • for dichotomous outcome data, the proportion of missing outcomes compared with observed event risk not enough to have a clinically relevant impact on the intervention effect estimate;

  • for continuous outcome data, plausible effect size (difference in means or standardized difference in means) among missing outcomes not enough to have a clinically relevant impact on observed effect size;

  • missing data have been imputed using appropriate methods.

Criteria for the judgement of ‘high risk’ of bias.

Any 1 of the following:

  • reason for missing outcome data likely to be related to true outcome, with either imbalance in numbers or reasons for missing data across intervention groups;

  • for dichotomous outcome data, the proportion of missing outcomes compared with observed event risk enough to induce clinically relevant bias in intervention effect estimate;

  • for continuous outcome data, plausible effect size (difference in means or standardized difference in means) among missing outcomes enough to induce clinically relevant bias in observed effect size;

  • ‘as‐treated’ analysis done with substantial departure of the intervention received from that assigned at randomization;

  • potentially inappropriate application of simple imputation.

Criteria for the judgement of ‘unclear risk’ of bias.

Any 1 of the following:

  • insufficient reporting of attrition/exclusions to permit judgement of ‘low risk’ or ‘high risk’ (e.g. number randomized not stated, no reasons for missing data provided);

  • the study did not address this outcome.

Selective reporting: reporting bias due to selective outcome reporting.

Criteria for a judgement of ‘low risk’ of bias.

Any of the following:

  • the study protocol is available and all of the study’s prespecified (primary and secondary) outcomes that are of interest in the review have been reported in the prespecified way;

  • the study protocol is unavailable but it is clear that the published reports include all expected outcomes, including those that were prespecified (convincing text of this nature may be uncommon).

Criteria for the judgement of ‘high risk’ of bias.

Any 1 of the following:

  • not all of the study’s prespecified primary outcomes have been reported;

  • 1 or more primary outcomes is reported using measurements, analysis methods or subsets of the data (e.g. subscales) that were not pre‐specified;

  • 1 or more reported primary outcomes were not pre‐specified (unless clear justification for their reporting is provided, such as an unexpected adverse effect);

  • 1 or more outcomes of interest in the review are reported incompletely so that they cannot be entered in a meta‐analysis;

  • the study report fails to include results for a key outcome that would be expected to have been reported for such a study.

Criteria for the judgement of ‘unclear risk’ of bias.

Insufficient information to permit judgement of ‘low risk’ or ‘high risk’. It is likely that most studies will fall into this category.

Other bias: bias due to problems not covered elsewhere in the table.

Criteria for a judgement of ‘low risk’ of bias.

The study appears to be free of other sources of bias.

Criteria for the judgement of ‘high risk’ of bias.

There is at least 1 important risk of bias. For example, the study:

  • had a potential source of bias related to the specific study design used; or

  • has been claimed to have been fraudulent; or

  • had some other problem.

Criteria for the judgement of ‘unclear risk’ of bias.

There may be a risk of bias, but there is either:

  • insufficient information to assess whether an important risk of bias exists; or

  • insufficient rationale or evidence that an identified problem will introduce bias.

Table 1. Frequency and five‐5 year overall survival for colorectal cancer

Stage

Frequency

Metastases

5‐ year disease‐free survival

5‐ year overall survival

Usual recommended treatment after surgery

I

39% (I and II)

No

95%

83%

Observation

II

39% (I and II)

No

85%

70%

Consider adjuvant chemotherapy

III

36%

No

69%

58%

Recommend adjuvant chemotherapy (e.g. FOLFOX)

IV

20%

Yes

(0%)

13%

Surgery not possible in most cases

Figures and Tables -
Table 1. Frequency and five‐5 year overall survival for colorectal cancer